The emergence of competitive rare diseases
Expanding upon how the rare disease space has developed since early ODs were approved, roundtable participants assessed how commercialization strategies have...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Kira Gordon is a Principal in the Life Sciences Practice at CRA specializing in strategy consulting. She has consulted on projects across number of therapeutic areas and healthcare markets.
Her project work focuses primarily on pricing & market access strategy and opportunity assessment/diligence support. Ms. Gordon has experience with both drugs and devices across a broad range of therapy areas, with a particular emphasis on medical-surgical devices, hospital drugs, metabolic syndrome, and outpatient specialty therapeutics in categories including oncology, neurology-psychology, autoimmune, and rare disease.